December 2, 2021 -- MImAbs has acquired the Berkeley Lights Beacon system via a TechAccess subscription to further the company's mission of generating and validating novel therapeutic antibodies to treat cancer and inflammatory diseases.
This marks the first Beacon platform to be used in France, according to the firms. MImAbs provides research institutions, public technology transfer offices, biotech, and biopharma customers with a fully integrated platform for antibody-based therapeutic development. The Beacon system will replace MImAbs' hybridoma system, according to the firms.
The Beacon system provides multiple benefits, including increased capacity to screen 40,000-100,000 B cells compared to only 1,500-3,000 with the hybridoma system, a reduction in timing by nearly 90%, and the ability to establish cell-based assays with adherent cells.
MImAbs was founded in 2011.